Regular Article CLINICAL TRIALS AND OBSERVATIONS Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
نویسندگان
چکیده
Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, Oncology Division, Stanford University Medical Center, Stanford, CA; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; US Oncology Research, Willamette Valley Cancer Institute and Research Center, Eugene, OR; Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center/New York Presbyterian Hospital, New York, NY; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA; Seattle Genetics, Inc., Bothell, WA; and Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
The majority of Hodgkin lymphoma (HL) patients can be cured with risk-adapted treatment, including chemotherapy and radiotherapy. Even when initially diagnosed with advanced-stage disease,.70% of these patients achieve long-term remission. However, depending on initial risk factors and treatment, 10% to 30% progress or relapse. Of these patients, only up to 50% can be cured with highdose chemot...
متن کاملBrentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
IMPORTANCE The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of ...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study
• CNS involvement at relapse/ progression in PTCL occurred at a frequency similar to what is seen in aggressive B-cell lymphomas. • Outcome after relapse is generally very poor in patients with PTCL and is not significantly altered by presence of CNS involvement at relapse. Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis. Risk factors and outcome...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Vishal Kukreti, Robert A. Vescio, Lixia Pei, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, and Raymond L. Co...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study Conrad Russell Y. Cruz, Kenneth P. Micklethwaite, Barbara Savoldo, Carlos A. Ramos, Sharon Lam, Stephanie Ku, Oumar Diouf, Enli Liu, A. John Barrett, Sawa Ito, Elizabeth J. Shpall, Robert A. Krance, Rammurti T. Kamble, George Carrum, Chitra M. ...
متن کامل